The US Food and Drug Administration has granted approval to a Canadian hospital for a procedure that can be performed on a patient who is not in a nursing home.
Mumford procedure can be used in hospitals that are unable to provide medical beds for patients who have terminal illness.
The procedure is performed by nurses using a robotic arm and has been in the works for a few years.
But the FDA said this week that a Canadian company, Acessa, could make a major step forward by making the operation safe and safe for the patient.
It is the first time that an American-developed technology that has been approved for use in the US is being used to deliver a breast cancer diagnosis in Canada.
“We think this is a very exciting development,” said Dr. John DeCarlo, the FDA’s chief medical officer, in a statement.
“The potential for improved outcomes with this technology in Canada is really exciting.”
This could allow a patient to be seen in a hospital in just a few days and receive a diagnosis that is much faster and less expensive.
“The company has also launched a website where people can share their experiences and ask questions.
Dr. DeCarlon said he expects to have a meeting with the FDA and Canada’s health minister on Thursday.